| Literature DB >> 36045829 |
Sukanta Ray1, Chaitali Basu2, Arkadeep Dhali1, Gopal Krishna Dhali3.
Abstract
Chronic pancreatitis is (CP) is a progressive inflammatory disease of the pancreas associated with disabling abdominal pain and gradual deterioration of exocrine and endocrine function. Up to 50% of patients with CP may require surgery during the course of the disease. The main indication for surgery is intractable abdominal pain not amenable to medical and endoscopic therapy. The type of surgery depends on pancreatic ductal diameter and associated parenchymal pathology like inflammatory head mass. Frey procedure (FP) is an effective method for control of pain in patients with enlarged pancreatic head. FP can be performed with a very low mortality and an acceptable morbidity. Compared with pancreaticoduodenectomy (PD), FP has favourable outcomes in terms of operation time, blood loss, morbidity, post-operative hospital stay, intensive care unit stay, and quality of life. FP has shorter operation time and lower morbidity in comparison to Beger procedure. But, long-term pain control and exocrine and endocrine dysfunctions are comparable between PD, Beger and FP. FP is technically easier than PD and Beger procedure. FP is thus a widely acceptable procedure for CP with enlarged pancreatic head in absence of a neoplasia.Entities:
Keywords: Chronic pancreatitis; Frey procedure; Outcome; Surgery
Year: 2022 PMID: 36045829 PMCID: PMC9422204 DOI: 10.1016/j.amsu.2022.104229
Source DB: PubMed Journal: Ann Med Surg (Lond) ISSN: 2049-0801
Izbicki Pain Score [19].
| Points | |
|---|---|
| Frequency of pain attacks | |
| Daily | 100 |
| Several times a week | 75 |
| Several times a month | 50 |
| Several times a year | 25 |
| None | 0 |
| VAS | |
| No pain | 0 |
| Imaginative maximum of pain | 100 |
| Analgesic medication (Morphine-related analgesic potency) | |
| Morphine | 100 |
| Buprenorphine | 80 |
| Pethidine | 20 |
| Tramadol | 15 |
| Metamizole | 3 |
| Acetylsalicylic acid, etc. | 1 |
| Time of disease-related inability to work | |
| Permanent | 100 |
| Up to 1 year | 75 |
| Up to 1 month | 50 |
| Up to 1 week | 25 |
| No inability to work during the last year | 0 |
Total Score = Sum of Single Median Values; Pain Score = Total Score Divided by 4.
Fig. 1Computed tomography scan of the abdomen showing an inflammatory pancreatic head mass (blue arrow). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 2Operative photograph showing cored out pancreatic head (green arrow) with longitudinally opened main pancreatic duct (blue arrow), duodenum (yellow arrow), and hemostatic sutures (yellow circles). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Short-and long-term outcomes after the Frey procedure.
| Author (reference no) | N | Morbidity | PPH | POPF | Mortality | Post-OP Stay | Pain control | New-onset DM | New-onset EPI | Weight gain | Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | (days) | n (%) | n (%) | n (%) | n (%) | (months) | ||
| Frey and Amikura (12) | 50 | 11 (22) | NS | 1/50 (2) | 0 (0) | 13.5 (mean) | 41/47 (87) | 3/31 (12.9) | 5/19 (26.3) | 25/39 (64) | 37 (mean) |
| Falconi et al. (20) | 40 | 3 (7.5) | 0 (0) | 2/40 (5) | 0 (0) | 9 (median) | 34/38 (88.8) | 3/30 (10) | NS | 26/40 (65) | 60 (median) |
| Pessaux et al. (21) | 34 | 7 (20.5) | 3/34 (8.8) | 4/34 (11.8) | 0 (0) | 16 (mean) | 30/34 (88.2) | 7/30 (23.3) | 4/12 (33.3) | 7/34 (79.4) | 15 (mean) |
| Negi et al. (1) | 60 | 25 (41.6) | 2/60 (3.3) | 4/60 (6.6) | 2 (3.3) | NS | 45/60 (75) | 4/29 (13.7) | NS | NS | 77 (median) |
| Gestic et al. (22) | 73 | 21 (28.7) | 2/73 (2.7) | 5/73 (6.8) | 0 (0) | 10.6 (median) | 64/70 (91.4) | 22/60 (36.7) | 25/51 (49) | NS | 77 (median) |
| Roch et al. (23) | 44 | 15 (34.5) | 4/44 (9) | 4/44 (9) | 0 (0) | 14 (median) | 21/41 (68.3) | 8 (18.1) | 7 (16) | 31 (70.5) | 51.5 (mean) |
| Cauchy et al. (24) | 33 | 17 (52) | 0 (0) | 5/33 (15) | 0 (0) | 19 vs 12 | 25/33 (76) | 4/17 (23.5) | 4/24 (16.6) | NS | 51 (median) |
| Ueda et al. (25) | 41 | 7 (17) | 3/41 (7.3) | 4/41 (10) | 0 (0) | 20 (mean) | 26/29 (90) | 2/29 (7) | NS | NS | 47 (mean) |
| Li et al. (26) | 75 | NS | NS | NS | NS | NS | 36/75 (48) | 11/51 (21.57) | 9/69 (13.04) | NS | 50.4 (median) |
| Ray et al. (27) | 138 | 43 (31) | 6/138 (4) | 11/138 (8) | 0 (0) | 9 (median) | 103/122 (84) | 28/89 (31.46) | 31/113 (27.43) | 89/122 (73) | 65 (median) |
N: number of patients; NS: not specified; PPH: post-pancreatectomy hemorrhage; POPF: postoperative pancreatic fistula; Post-OP: postoperative; DM: diabetes mellitus; EPI: exocrine pancreatic insufficiency.
Comparison of Frey procedure with Beger procedure and Pancreaticoduodenectomy.
| Author | Number | Number | Operative morbidity Mortality | Pain control | DM | EPI | QOL | Duration of follow-up (months) | |
|---|---|---|---|---|---|---|---|---|---|
| (reference) | n (%) | n (%) | n (%) | n (%) | n (%) | ||||
| Izbicki et al. | Frey | 31 | 19.4% | 1/31 (3.2) | 28/31 (90) | 32% | 58% | 71% | 24 (median) |
| [ | PPPD | 30 | 53.3% | 0 (0) | 26/30 (87) | 40% | 83% | 43% | |
| Hilderbrand et al. | Frey | 39 | 20.5% | 0 (0) | 36/39 (92.3) | 8/30 (26.7) | 20/30 (66.7) | equal | 50 (median) |
| [ | PD | 12 | 41.7% | 0 (0) | 8/12 (66.7) | 4/6 (66.7) | 5/6 (83.3) | ||
| Aimoto et al. | Frey | 6 | 1/6 (16.7) | 0 (0) | 6/6 (100) | 1/6 (16.7) | 0 (0) | better | 70.8 (mean) |
| [ | PPPD | 10 | 2/10 (20) | 0 (0) | 9/10 (90) | 4/10 (40) | 1/10 (10) | 119.8 (mean) | |
| Chiang et al. | Frey | 25 | 20% | 0 (0) | NS | NS | NS | NS | 6 (mean) |
| [ | PD | 17 | 11.8% | 0 (0) | NS | NS | NS | ||
| Strate et al. | Frey | 31 | 19.4 | 1/31 (3.2) | NS | 13/23 (56.5%) | 18/21 (86%) | equal | 84 (median) |
| [ | PPPD | 30 | 53.3 | 0 (0) | NS | 15/23 (65%) | 22/23 (96%) | ||
| Bachmann et al. | Frey | 31 | 19.4% | 1/31 (3.2) | 7/21 (33.3) | 81% | 86% | better | 180 (median) |
| [ | PPPD | 30 | 53.3% | 0 (0) | 6/14 (43) | 86% | 93% | ||
| Kelemen et al. | Frey | 13 | 0 (0) | 0 (0) | 7/12 (57.1) | 10/12 (83.3) | equal | 20.6 (mean) | |
| Beger | 32 | 8 (25) | 0 (0) | 17/27 (63.2) | 23/27 (85.1) | 41.5 (mean) | |||
| [ | PPPD | 21 | 13 (61.9) | 2 (9.5) | 11/14 (78.5) | 11/14 (78.5) | 31.1 (mean) | ||
| Izbicki et al. | Frey | 22 | 9% | 0 (0) | 89 | 59 | 50 | equal | 18 (mean) |
| [ | Beger | 20 | 20% | 0 (0) | 95 | 65 | 50 | ||
| Keck et al. | Frey | 50 | 30% | 0 (0) | 94 | 30/50 (60) | 38/50 (76) | NS | 43 (median) |
| [ | Beger | 42 | 40% | 0 (0) | 81 | 24/42 (57) | 31/42 (74) | 62 (median) | |
| Strate et al. | Frey | 36 | 22% | 0 (0) | NS | 15/25 (60) | 18/23 (78) | equal | 104 (median) |
| [ | Beger | 38 | 32% | 0 (0) | NS | 14/25 (56) | 22/25 (88) | ||
| Bachmann et al. | Frey | 36 | 22% | 0 (0) | NS | 83% | 86% | equal | 192 (median) |
| [ | Beger | 38 | 32% | 0 (0) | 77% | 87% | |||
NS: not specified; Italics: new-onset DM; DM: diabetes mellitus; EPI: exocrine pancreatic insufficiency; QOL: quality of life.